• Explore /
  • Poster
  • / Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.

Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial.

Abstract Poster

Authors

null

Nieves Martinez Chanza

Medical Oncology Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium

Nieves Martinez Chanza , Aurelien Carnot , Philippe Barthélémy , Vinciane Casert , Lionel Staudacher , Jan Van Den Brande , Brieuc Sautois , Vincent Vanhaudenarde , Emmanuel Seront , Veronique Debien , Thierry Gil , Marianne Paesmans , Nuria Kotecki , Michail Ignatiadis , Simone Albisinni , Jean Christophe Fantoni , Thibault Tricard , Romain Diamond , Thierry Andre Roumeguere , Ahmad Awada

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT03674424

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4517)

DOI

10.1200/JCO.2022.40.16_suppl.4517

Abstract #

4517

Poster Bd #

9

Abstract Disclosures

Similar Posters

First Author: Xiao Yang

First Author: Tianxin Lin

First Author: Amarnath Challapalli

First Author: Tianxin Lin